EXHIBIT 10.13 STRESSGEN BIOTECHNOLOGIES CORPORATION 2001 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT S (INCENTIVE OR NONSTATUTORY WITH ACCELERATION AND PARACHUTE) Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Stock Option...Stressgen Biotechnologies Corp • March 19th, 2002 • Biological products, (no disgnostic substances)
Company FiledMarch 19th, 2002 Industry
EXHIBIT 99.2 STRESSGEN BIOTECHNOLOGIES CORPORATION 2001 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Stock Option Agreement,...Stock Option Agreement • May 30th, 2001 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances)
Contract Type FiledMay 30th, 2001 Company Industry
RESTRUCTURED AND RESTATED HspE7 COLLABORATION AGREEMENT AMONG STRESSGEN DEVELOPMENT CORPORATION AND STRESSGEN BIOTECHNOLOGIES CORPORATION AND December 1, 2003Certain • February 19th, 2004 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 19th, 2004 Company Industry JurisdictionThis RESTRUCTURED AND RESTATED HSPE7 COLLABORATION AGREEMENT (“Agreement”) is made as of December 1, 2003 (the “Effective Date”) by and among, on the one hand, STRESSGEN DEVELOPMENT CORPORATION, a Barbados corporation, with its principal office at Whitepark House, White Park Road, P.O. Box 806E, Bridgetown, Barbados (“Stressgen”), and STRESSGEN BIOTECHNOLOGIES CORPORATION, a corporation organized under the laws of Yukon Territory, Canada, with its principal office at #350 – 4243 Glanford Avenue, Victoria, BC Canada V8Z 4B9 (“SBC”), and, on the other hand, F.HOFFMANN-LA ROCHE LTD, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070-Basel Switzerland and HOFFMANN-LA ROCHE INC., a New Jersey corporation, with its principal office at 340 Kingsland Street, Nutley, New Jersey 07110 (collectively, “Roche”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 28th, 2004 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances) • British Columbia
Contract Type FiledOctober 28th, 2004 Company Industry JurisdictionSTRESSGEN BIOTECHNOLOGIES INC. (a Delaware corporation) and STRESSGEN BIOTECHNOLOGIES CORPORATION (a Yukon corporation) having an office at 350 – 4243 Glanford Avenue, Victoria, British Columbia
Biological Service AgreementBiological Service Agreement • May 6th, 2004 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 6th, 2004 Company Industry Jurisdiction
HspE7 COLLABORATION AGREEMENT AMONG STRESSGEN DEVELOPMENT CORPORATION AND STRESSGEN BIOTECHNOLOGIES CORPORATION AND F.HOFFMANN-LA ROCHE LTD AND HOFFMANN- LA ROCHE INC. June 21, 2002Hspe7 Collaboration Agreement • August 7th, 2002 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances)
Contract Type FiledAugust 7th, 2002 Company IndustryThis HspE7 Collaboration Agreement (“Agreement”) is made as of June 21, 2002 (“Execution Date”) by and among, on the one hand, Stressgen Development Corporation, a Barbados corporation, with its principal office at Whitepark House, White Park Road, P.O. Box 806E, Bridgetown, Barbados (“Stressgen”), and, for the limited purposes set forth in Section 2.1, Stressgen Biotechnologies Corporation, a corporation organized under the laws of Yukon Territory, Canada, with its principal office at #350 — 4243 Glanford Avenue, Victoria, BC Canada V8Z 4B9 (“SBC”), and, on the other hand, F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070-Basel Switzerland and Hoffmann-La Roche Inc., a New Jersey corporation, with its principal office at 340 Kingsland Street, Nutley, New Jersey 07110 (collectively, “Roche”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • April 18th, 2005 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances) • California
Contract Type FiledApril 18th, 2005 Company Industry JurisdictionThis ASSET PURCHASE AGREEMENT (this “Agreement”) is effective as of April 13, 2005 (the “Effective Date”), by and between Stressgen Bioreagents Corporation, a Delaware corporation (“Buyer”) and Stressgen Bioreagents Limited Partnership, a British Columbia limited partnership (“Seller”), the general partner of which is Stressgen Holdings Corporation, a Yukon Territories corporation (“SHC”) and the sole limited partner of which is Stressgen Biotechnologies Corporation, a Yukon Territories corporation (“SBC,” and together with SHC, “Partners”), with reference to the following facts:
Fourth AmendmentLicense Agreement • May 10th, 2005 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances)
Contract Type FiledMay 10th, 2005 Company IndustryThis Fourth Amendment is to the License Agreement dated November 29,1992 by and between the MASSACHUSETTS INSTITUTE OF TECHNOLOGY (“M.I.T.”), the WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (“Whitehead”) and STRESSGEN BIOTECHNOLOGIES CORPORATION (“LICENSEE”).